Under the deal, the two firms will work together to advance the next frontier of bi-specific antibody development platforms and bring new therapies to patients in need.
CMC Biologics global chief operations officer Gustavo Mahler said, "Being selected by Zymeworks, who are known for developing best-in-class and highly effective protein therapeutics, is a natural fit for us and validates our technical excellence and partnering philosophy."
Zymeworks president and CEO Ali Tehrani said, "As we advance our lead Azymetric oncology program and first therapeutic built on our proprietary ZymeCAD platform, choosing a contract partner with a track record of success in development and manufacturing is critical."
The collaboration will help Zymeworks in moving its oncology program into clinical trials to treat breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma.